Nisar Ahmed
RIO DE JANEIRO,Brazil: A once-weekly oral HIV treatment has emerged as one of the biggest scientific breakthroughs at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, offering hope for simpler and more accessible HIV care worldwide.
Researchers presented encouraging Phase 3 trial results for an investigational combination of lenacapavir and islatravir, which is designed to replace daily HIV medication with a single pill taken once a week.
The ISLEND-1 and ISLEND-2 studies showed the regimen effectively maintained viral suppression in adults living with HIV. Experts said the simplified dosing schedule could improve treatment adherence and reduce the burden of taking medication every day.
Health specialists noted that the innovation could be especially valuable in low- and middle-income countries, where healthcare systems often face financial and logistical challenges. A once-weekly regimen may reduce clinic visits, improve patient convenience and help expand access to treatment.
Researchers cautioned that the treatment is still under regulatory review and has not yet been approved for routine clinical use. They added that future efforts will focus on ensuring affordability and broad access if approval is granted.
Scientists described the findings as a significant milestone in HIV treatment, with the potential to pave the way for even longer-acting therapies in the future.
The AIDS 2026 conference is being held in Rio de Janeiro from July 26 to 31, bringing together researchers, healthcare professionals and policymakers to discuss the latest advances in HIV prevention and treatment.
